User account menu

Home
A Retrospective Database Study to Evaluate Rates of Influenza and Related Diagnoses between Patients Treated with Tofacitinib and Other Systemic Therapies within Cohorts of RA, PsA, and UC Patients: A Post-Authorization Safety Study of Tofacitinib

A Retrospective Database Study to Evaluate Rates of Influenza and Related Diagnoses between Patients Treated with Tofacitinib and Other Systemic Therapies within Cohorts of RA, PsA, and UC Patients: A Post-Authorization Safety Study of Tofacitinib

First published 16/02/2021

Last updated 23/04/2024

EU PAS number:

EUPAS39242

Study

Finalised

Documents

Study protocol

Initial protocol

FINAL A3921383 Non-Interventional Protocol Study 01 December 2020

English (1.86 MB - PDF) View document

Updated protocol

A3921383 Non-Interventional Protocol Study Amendment 1 (CLEAN) 29 October 2021_Redacted

First published: 22/02/2024

English (3.09 MB - PDF) View document

Study results

A3921383 Non Interventional Study Report Abstract 10 February 2023_Redacted

English (287.26 KB - PDF) View document

Study report

A3921383 Non Interventional Study Report 10 February 2023_Redacted

English (8.19 MB - PDF) View document

Other information

HMA-EMA Catalogues of real-world data sources and studies

Privacy

Contact